Archives: 2019-10-05

Researchers unlock potential to use CRISPR to alter the microbiome

Researchers at Western University have developed a new way to deliver the DNA-editing tool CRISPR-Cas9 into microorganisms in the lab, providing a way to efficiently launch a targeted attack on specific bacteria. Published today in Nature Communications, this study opens up the possibility of using CRISPR to alter the makeup of the human microbiome in a way that could be personalized

Read More


Duvelisib Gains FDA Orphan Drug Designation for T-Cell Lymphomas

The FDA has granted duvelisib (Copiktra) with an orphan drug designation for the treatment of patients with T-cell lymphoma, according to a press release from Verastem Oncology, the company developing duvelisib.1 The PI3K-δ,γ inhibitor demonstrated efficacy in a phase I study and is currently being investigated in the phase II PRIMO trial (NCT03372057). “Receiving orphan

Read More


Stem Cells Present Parallel Opportunities for Pelizaeus-Merzbacher disease

Two new studies by an international team of researchers report progress in using stem cells to develop new therapies for Pelizaeus-Merzbacher disease (PMD), a rare genetic condition affecting boys that can be fatal before 10 years of age. Often diagnosed at birth with symptoms of weakness and breathing difficulties, the progressive neurological problems in PMD

Read More


Society of Hematologic Oncology 2019 : The future of cellular therapy in hematological malignancies

The number of cancer cell therapies has increased considerably over the last few years.1 There are several different types of cellular therapies, including chimeric antigen receptor (CAR) T cells, multiple tumor-associated antigen-specific T cells (TAA-T), natural killer (NK)-based therapies and T-cell therapies based on novel technologies like CRISPR.1 Amongst the different types of cell therapies in development,

Read More


NIH Research Centers Will Advance Precision Medicine for Alzheimer’s

The two new centers will diversify and improve the Alzheimer’s drug development pipeline, contributing to precision medicine advancements for the disease. The National Institutes on Aging (NIA), part of NIH, have launched two new research centers designed to advance precision medicine for Alzheimer’s disease and reinvigorate the drug development pipeline. The Alzheimer Centers for the Discovery of

Read More